Intracellular actions of steroid hormones and their therapeutic value, including the potential of radiohalosteroids against ovarian cancer

1992 ◽  
Vol 71 ◽  
pp. 39-54 ◽  
Author(s):  
John A. Holt ◽  
Anton Scharl ◽  
Stig Kullander ◽  
Matthias W. Beckmann
Onkologie ◽  
2009 ◽  
Vol 32 (11) ◽  
pp. 623-624 ◽  
Author(s):  
Simon P. Langdon ◽  
Dana Faratian ◽  
David J. Harrison

2020 ◽  
Vol 11 (4) ◽  
pp. 7166-7174
Author(s):  
Lana Muhammad Ali ◽  
Parween Abdulsamad Ismail

Ovarian cancer has high mortality and delayed diagnosis. Inflammation is considered as a risk for ovarian carcinoma, and it contributes to all grades of tumour progression. Inflammation involved in the development of cancer cell and can be caused by an increase in the formation of pro-inflammatory cytokines. This research was conducted to assess serum Interleukin, Gonadotropins hormone and Steroid hormone levels in ovarian cancer patients and to assess their impact in disease action. The present study is composed of 85 women (mean age = 62.03±12.4 yrs) with clinically and pathologically confirmed ovarian cancer and 65 healthy women as a control group (mean age = 61±12.1 yrs). The measured biochemical parameters included: the level of serum gonadotropins(LH, luteinizing hormone; FSH, follicle-stimulating hormone), steroid hormones (estrogen, progesterone, prolactin, testosterone) and Interleukin (IL-4, IL-6, and IL-8). The results demonstrated significantly high values of steroid hormones (p<0.01, p<0.01, p<0.05,p<0.002, p<0.01 (estrogen, progesterone, prolactin, testosterone) and significantly high ( p<0.001, p<0.002, p<0.01)values in (IL-4, IL-6, and IL-8) in ovarian cancer in comparison with control group. There were also significantly high (p<0.0001, p<0.05 values of sera LH and FSH in women ovarian cancer in comparison with the control group. p<0.01, p<0.001) respectively in ovarian cancer in comparison with the control group. An elevation of serum steroid hormone, gonadotropins, and Interleukin levels in cases of ovarian carcinoma in our study is important as a marker of the disease.


2011 ◽  
Vol 85 (Suppl_1) ◽  
pp. 343-343
Author(s):  
Kendra M. Hodgkinson ◽  
Laura Laviolette ◽  
Carolina Perez-Iratxeta ◽  
Barbara C. Vanderhyden

1986 ◽  
Vol 9 (4) ◽  
pp. 307-314 ◽  
Author(s):  
D. Mango ◽  
P. Scirpa ◽  
F. Battaglia ◽  
E. Tartaglia ◽  
P. Manna

1988 ◽  
Vol 95 (12) ◽  
pp. 1231-1236 ◽  
Author(s):  
KAMMA BERTELSEN ◽  
MOGENS KERN HANSEN ◽  
POUL HJORTKAER PEDERSEN ◽  
GORM LARSEN ◽  
MOGENS NYLAND ◽  
...  

Author(s):  
Günter Emons ◽  
Olaf Ortmann ◽  
Gurcharan S. Pahwa ◽  
Reinhard Hackenberg ◽  
F. Oberheuser ◽  
...  

2021 ◽  
Vol 15 (11) ◽  
pp. 3372-3375
Author(s):  
Gulshan Parveen ◽  
Ali Hassan ◽  
Muhammad Hassam Rehm ◽  
Awais Altaf ◽  
Nureen Zahra ◽  
...  

Background: Ovarian cancer (OC) is a worst type of malignancy in the field of gynecology. This is because ovarian tumors diagnosed at advanced stage of disease. The exact mechanism for its development is still unknown. Aim: The aim of this study is to measure the levels of steroidal hormones and their function in ovarian cancer progression. Methods: In the present study, fifty ovarian cancer patients and fifty control individuals were taken and serum was separated from their blood samples. The levels of steroid hormones were measured by ELISA kit methods. Results: Result of the current study determined the levels of E2, progesterone, testosterone, FSH, LH, 17-β-HSD-I, 17-β-HSD-II, cortisol and aromatase were extensively higher in patient group in comparison with healthy individuals. Conclusion: Current study concluded the Study concluded that overexpression of steroid hormones may lead to enhance tumor survival in ovarian cancer through various signaling mechanisms. Keywords: Ovarian cancer, Estradiol, FSH, LH, progesterone


Sign in / Sign up

Export Citation Format

Share Document